title: [Premixed insulin and intermediate-acting insulin].
abstract: Intermediate-acting insulin and premixed insulin have a long history. They were widely used till the 1990s. However, due to the emergence of long-acting solubility insulin analogue and recent expanding EBM, premixed insulin became mainly used for type 2 patients who have stable lifestyles like elderly people. In the consensus algorithm for type 2 patients reached at ADA/EASD2012, premixed insulin is considered moderately complex but not so flexible. Instead, basal-bolus therapy is recommended because it is more flexible than other regimens. Although not recommended strongly by the guideline, premixed insulin can be adopted after considering the condition, lifestyle and situation of patients. As for intermediate-acting insulin, the spread of long-acting insulin analogues has rendered its therapeutic role no longer significant today.
authors: Hisaaki
authors: H
authors: Morishita
mesh_terms: D000465:Algorithms; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin